Keyword Analysis & Research: apixaban vs warfarin esrd
Keyword Research: People who searched apixaban vs warfarin esrd also searched
Search Results related to apixaban vs warfarin esrd on Search Engine
-
Outcomes associated with apixaban vs warfarin in patients with …
https://ashpublications.org/bloodadvances/article/4/11/2366/457796/Outcomes-associated-with-apixaban-vs-warfarin-in
Web ResultMay 28, 2020 · The primary outcome was the time to first bleeding or thrombosis event. A total of 128 patients met inclusion criteria in the apixaban group and 733 patients in the warfarin group. Time to first bleeding or thrombosis event was significantly different between the apixaban and warfarin groups.
DA: 73 PA: 37 MOZ Rank: 10
-
Safety and Efficacy of Apixaban versus warfarin in patients with …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263313/
Web ResultApr 15, 2021 · Apixaban had an overall favorable risk-benefit profile, with significant reductions in ischemic stroke, major bleeding, and intracranial bleeding compared to Warfarin in ESRD patients on hemodialysis with non-valvular AF and/or venous thromboembolism. Keywords: Apixaban, Warfarin, Dialysis, End-stage renal …
DA: 32 PA: 8 MOZ Rank: 95
-
Apixaban Compared With Warfarin in Patients With Atrial …
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061647
Web ResultDec 5, 2022 · The US Food and Drug Administration decision appears to be supported by subsequent registry data suggesting that apixaban is associated with lower rates of bleeding than warfarin in patients with AF requiring dialysis, 5 although stroke rates were similar.
DA: 87 PA: 21 MOZ Rank: 38
-
Safety and Efficacy of Apixaban vs Warfarin in Patients With …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651588/
Web ResultOct 12, 2022 · The results indicate that the overall efficacy of apixaban was equivalent to warfarin for the prevention of stroke, systemic embolization, and recurrent venous thromboembolism, but apixaban showed an equivalent and, in some studies, better safety profile than warfarin concerning the occurrence of …
DA: 30 PA: 89 MOZ Rank: 99
-
Apixaban for End-Stage Kidney Disease | Circulation - AHA/ASA …
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036449
Web ResultOct 8, 2018 · In aggregate, apixaban was associated with less major bleeding compared with warfarin (HR, 0.72; 95% CI, 0.59–0.87), but no difference was found in stroke/systemic embolism, intracranial or gastrointestinal bleeding, or death.
DA: 79 PA: 63 MOZ Rank: 7
-
Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in
https://pubmed.ncbi.nlm.nih.gov/34420589/
Web ResultApixaban may have a lower risk of major bleeding and comparable risk of stroke when compared with warfarin in AF patients with ESRD. Apixaban; Atrial fibrillation; End stage renal disease; Rivaroxaban; Warfarin. Copyright © 2020 Elsevier Inc. All rights reserved. Anticoagulants* / adverse effects. Atrial Fibrillation* / complications.
DA: 28 PA: 48 MOZ Rank: 17
-
Safety and efficacy of apixaban versus warfarin in patients with …
https://pubmed.ncbi.nlm.nih.gov/29577340/
Web ResultAmong patients with advanced CKD and ESRD, the use of apixaban was associated with lower risk of major bleeding compared to warfarin, and was found to be relatively effective with no excess risk of thromboembolic events. apixaban; atrial fibrillation; bleeding complication; meta-analysis; thromboembolic events; vitamin …
DA: 14 PA: 50 MOZ Rank: 13
-
Effectiveness and Safety of Apixaban versus Warfarin in Venous
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251708/
Web ResultDec 28, 2021 · In summary, apixaban was associated with a significantly lower risk of recurrent VTE and MB than warfarin among VTE patients with CKD. CKD stages did not have significant impact on treatment effects for recurrent VTE and MB. Keywords: chronic kidney disease, apixaban, venous thromboembolism. …
DA: 93 PA: 95 MOZ Rank: 40
-
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and
https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.044059
Web ResultMar 12, 2020 · Results: Among patients with CrCl 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34 [95% CI, 0.14–0.80]) and major or clinically relevant nonmajor bleeding (hazard ratio, 0.35 …
DA: 57 PA: 51 MOZ Rank: 54
-
Apixaban versus Warfarin in Patients with Atrial Fibrillation
https://www.nejm.org/doi/full/10.1056/NEJMoa1107039
Web ResultFeb 29, 2024 · Results. The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard...
DA: 36 PA: 61 MOZ Rank: 8